Leap Therapeutics, Inc. (LPTX)
NASDAQ: LPTX · Real-Time Price · USD
0.3969
+0.0038 (0.97%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Leap Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
52
Market Cap
16.50M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
LPTX News
- 2 days ago - Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting - PRNewsWire
- 12 days ago - Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer - PRNewsWire
- 27 days ago - Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript - Seeking Alpha
- 4 weeks ago - Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - Benzinga
- 4 weeks ago - Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 4 weeks ago - Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study - PRNewsWire
- 3 months ago - Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study - PRNewsWire
- 3 months ago - Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer - Seeking Alpha